In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

EntreMed, Allergan develop Panzem for eye disease; ended

Executive Summary

EntreMed (anti-angiogenesis drugs) has signed a five-year agreement with Allergan (ophthalmic therapeutics) to develop and market small molecule angiogenic inhibitors to prevent and treat ophthalmic diseases and disorders.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Co-Promotion
    • Intra-Biotech Deal
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register